D-0020-2022 Class II Terminated

Recalled by American Health Packaging — Columbus, OH

FDA drug recall D-0020-2022 was initiated by American Health Packaging on Sep 17, 2021 and is designated Class II. Reason for recall: Failed Dissolution Specifications: results were above specification. The recall status is terminated (terminated Jun 8, 2023). Affected quantity: 2,266 cartons.

Recall details

Product Type
Drugs
Report Date
Oct 27, 2021
Initiation Date
Sep 17, 2021
Termination Date
Jun 8, 2023
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
2,266 cartons

Product description

GlipiZIDE Extended-Release Tablets, 2.5 mg, 30 Tablets (3 blister cards each with 10 individually blistered doses), Rx only, Manufactured by: Patheon Pharmaceuticals Inc., Cincinnati, OH 45237; Distributed by: Actavis Pharma, Inc., Parsippany, NJ 07054. Carton NDC#: 68084-295-21 (Individual Dose NDC: 68084-295-11)

Reason for recall

Failed Dissolution Specifications: results were above specification.

Distribution pattern

Nationwide within the USA

Code information

Lot #: 194141, Exp. Date 03/31/2022

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0020-2022
openFDA file date
Nov 10, 2026
Loaded by RegDataLab
Nov 11, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0020-2022. Report a data issue: hello@regdatalab.com.